title: CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21).
abstract: We investigated the significance of surface antigen expression for prognosis by focusing on a specific subtype, AML with t(8;21). The investigation included 144 patients with AML with t(8;21) in the JALSG AML97 study. AML with t(8;21) expressed CD19 (36%), CD34 (96%), and CD56 (65%) more frequently than did other subtypes of AML. CD19 expression had a significant favorable effect on CR (95.7% vs. 83.8%; P=0.049). Univariate analysis showed that increased white blood cell (WBC) counts (WBC ≥ 20 × 10(9)/L), CD19 negativity, and CD56 positivity were critical adverse factors for relapse after CR; multivariate analysis revealed that WBC count and CD56 expression were independent adverse risk factors (HR 2.18; P=0.045, HR 2.30; P=0.011, respectively). We concluded that CD56 expression has a possible role in risk stratification for patients with AML with t(8;21).
authors.affiliation: Department of Hematology and Rheumatology, Nihon University Itabashi Hospital, Tokyo, Japan. iriyama.noriyoshi@nihon-u.ac.jp
authors.forename: Noriyoshi
authors.initials: N
authors.lastname: Iriyama
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Hatta
authors.forename: Jin
authors.initials: J
authors.lastname: Takeuchi
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Ogawa
authors.forename: Shigeki
authors.initials: S
authors.lastname: Ohtake
authors.forename: Toru
authors.initials: T
authors.lastname: Sakura
authors.forename: Kinuko
authors.initials: K
authors.lastname: Mitani
authors.forename: Fumihiro
authors.initials: F
authors.lastname: Ishida
authors.forename: Masatomo
authors.initials: M
authors.lastname: Takahashi
authors.forename: Tomoya
authors.initials: T
authors.lastname: Maeda
authors.forename: Tohru
authors.initials: T
authors.lastname: Izumi
authors.forename: Hisashi
authors.initials: H
authors.lastname: Sakamaki
authors.forename: Shuichi
authors.initials: S
authors.lastname: Miyawaki
authors.forename: Sumihisa
authors.initials: S
authors.lastname: Honda
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Miyazaki
authors.forename: Tomohiko
authors.initials: T
authors.lastname: Taki
authors.forename: Masafumi
authors.initials: M
authors.lastname: Taniwaki
authors.forename: Tomoki
authors.initials: T
authors.lastname: Naoe
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D019002:CD56 Antigen / Q000378:metabolism*; D002891:Chromosomes, Human, Pair 21 / Q000235:genetics*; D002898:Chromosomes, Human, Pair 8 / Q000235:genetics*; D020732:Cytogenetic Analysis; D005260:Female; D005434:Flow Cytometry; D005500:Follow-Up Studies; D006801:Humans; D016130:Immunophenotyping; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000235:genetics / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000235:genetics / Q000401:mortality*; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D014178:Translocation, Genetic / Q000235:genetics*; D055815:Young Adult
chemical_list: D019002:CD56 Antigen
keywords: Acute myeloid leukemia with t(8 ;21); CD56 antigen; Prognostic factor